These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 15741565)
1. Trial and error: prognostic gene signature study design altered. Tuma RS J Natl Cancer Inst; 2005 Mar; 97(5):331-3. PubMed ID: 15741565 [No Abstract] [Full Text] [Related]
2. Multiple gene signatures aim to qualify risk in breast cancer. Tuma RS J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566 [No Abstract] [Full Text] [Related]
3. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972 [TBL] [Abstract][Full Text] [Related]
4. Integrated gene expression profile predicts prognosis of breast cancer patients. Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552 [TBL] [Abstract][Full Text] [Related]
5. Re: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Kunkler I J Natl Cancer Inst; 2005 Aug; 97(15):1162-3; author reply 1163-4. PubMed ID: 16077078 [No Abstract] [Full Text] [Related]
6. More evidence that locoregional radiation therapy improves survival: what should we do? Whelan T; Levine M J Natl Cancer Inst; 2005 Jan; 97(2):82-4. PubMed ID: 15657332 [No Abstract] [Full Text] [Related]
7. Prognostic markers of local relapse in rectal cancer: are we any further forward? Johnston PG J Clin Oncol; 2006 Sep; 24(25):4049-50. PubMed ID: 16943520 [No Abstract] [Full Text] [Related]
8. A big trial for a new technology: TransBIG Project takes microarrays into clinical trials. Tuma RS J Natl Cancer Inst; 2004 May; 96(9):648-9. PubMed ID: 15126595 [No Abstract] [Full Text] [Related]
9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
10. Current status of prognostic profiling in breast cancer. Pusztai L Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548 [TBL] [Abstract][Full Text] [Related]
11. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Newman LA; Mamounas EP Surg Clin North Am; 2007 Apr; 87(2):279-305, vii. PubMed ID: 17498527 [TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249 [TBL] [Abstract][Full Text] [Related]
13. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer. Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O Int J Oncol; 2009 Feb; 34(2):441-8. PubMed ID: 19148479 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
15. The influence of a gene expression profile on breast cancer decisions. Henry LR; Stojadinovic A; Swain SM; Prindiville S; Cordes R; Soballe PW J Surg Oncol; 2009 May; 99(6):319-23. PubMed ID: 19204954 [TBL] [Abstract][Full Text] [Related]
17. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229 [TBL] [Abstract][Full Text] [Related]
18. Population-based molecular prognosis of breast cancer by transcriptional profiling. Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081 [TBL] [Abstract][Full Text] [Related]
19. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948 [TBL] [Abstract][Full Text] [Related]
20. Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. Nuyten DS; van de Vijver MJ Semin Radiat Oncol; 2008 Apr; 18(2):105-14. PubMed ID: 18314065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]